BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38613852)

  • 1. Comment on betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
    Sekar D
    Oral Oncol; 2024 May; 152():106800. PubMed ID: 38613852
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on "Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study".
    Aragão HHR; Monteiro MA; Lopes NVA; Cunha JLS
    Oral Oncol; 2024 May; 152():106788. PubMed ID: 38574564
    [No Abstract]   [Full Text] [Related]  

  • 3. Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
    Hong RL; Yen CJ; Lien MY; Cheng R; Su YW; Lin HN; Poon SL; Chien CY
    Oral Oncol; 2024 May; 152():106760. PubMed ID: 38520758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Pai SI; Cohen EEW; Lin D; Fountzilas G; Kim ES; Mehlhorn H; Baste N; Clayburgh D; Lipworth L; Resteghini C; Shara N; Fujii T; Zhang J; Stokes M; Wang H; Twumasi-Ankrah P; Wildsmith S; Khaliq A; Melillo G; Shire N
    J Transl Med; 2019 Dec; 17(1):429. PubMed ID: 31878938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma.
    Hirshoren N; Al-Kharouf I; Weinberger JM; Eliashar R; Popovtzer A; Knaanie A; Fellig Y; Neuman T; Meir K; Maly A; Vainer GW
    Oncology; 2021; 99(7):464-470. PubMed ID: 33789303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
    Okamoto I; Sato H; Tsukahara K
    Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
    Su YY; Chien CY; Luo SD; Huang TL; Lin WC; Fang FM; Chiu TJ; Chen YH; Lai CC; Hsu CM; Li SH
    World J Surg Oncol; 2016 Mar; 14():86. PubMed ID: 27001663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study.
    Cerbelli B; Girolami I; Eccher A; Costarelli L; Taccogna S; Scialpi R; Benevolo M; Lucante T; Luigi Alò P; Stella F; Gemma Pignataro M; Fadda G; Perrone G; D'Amati G; Martini M
    Histopathology; 2022 Jan; 80(2):397-406. PubMed ID: 34496080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerable interlaboratory variation in PD-L1 positivity for head and neck squamous cell carcinoma in the Netherlands- A nationwide evaluation study.
    Hempenius MA; Koomen BM; Deckers IAG; Oosting SF; Willems SM; van der Vegt B
    Histopathology; 2024 Jul; 85(1):133-142. PubMed ID: 38606992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients.
    Lim SM; Hong MH; Ha SJ; Hwang D; Chae S; Koh YW; Choi EC; Kim SH; Kim DH; Yoon SO; Kim HR
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2741-2750. PubMed ID: 33616718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
    Zhou AL; Wang X; Yu W; Yang L; Wei F; Sun Q; Wang Y; Kou F; Dong R; Ren X; Zhang X
    Pathol Res Pract; 2020 Sep; 216(9):153093. PubMed ID: 32825960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
    Baruah P; Bullenkamp J; Wilson POG; Lee M; Kaski JC; Dumitriu IE
    Front Immunol; 2019; 10():1644. PubMed ID: 31379843
    [No Abstract]   [Full Text] [Related]  

  • 14. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
    Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP
    Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma.
    Okada S; Itoh K; Ishihara S; Shimada J; Kato D; Tsunezuka H; Miyata N; Hirano S; Teramukai S; Inoue M
    Surg Oncol; 2018 Jun; 27(2):259-265. PubMed ID: 29937180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression in recurrent head and neck squamous cell carcinoma.
    Delafoy A; Uguen A; Lemasson G; Conan-Charlet V; Pradier O; Lucia F; Schick U
    Eur Arch Otorhinolaryngol; 2022 Jan; 279(1):343-351. PubMed ID: 33796940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Influences Cell Spreading, Migration and Invasion in Head and Neck Cancer Cells.
    Eichberger J; Schulz D; Pscheidl K; Fiedler M; Reichert TE; Bauer RJ; Ettl T
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33138288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune gene expression in head and neck squamous cell carcinoma patients.
    Lecerf C; Kamal M; Vacher S; Chemlali W; Schnitzler A; Morel C; Dubot C; Jeannot E; Meseure D; Klijanienko J; Mariani O; Borcoman E; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Choussy O; Hoffmann C; Piaggio E; Bieche I; Le Tourneau C
    Eur J Cancer; 2019 Nov; 121():210-223. PubMed ID: 31593831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
    Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
    Front Immunol; 2020; 11():1721. PubMed ID: 33072064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.